
Opinion|Videos|October 10, 2024
Key Highlights on POD1UM-303 Presented at ESMO 2024
Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.
Advertisement
Advertisement
Related to this article

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
4
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
5

